| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD9647 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | -0.016 | 0.8 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.0099 | 0.8 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | PD-0332991 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | BRD-K55116708 | CTRPv2 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | chlorambucil | CTRPv2 | pan-cancer | AAC | -0.0088 | 0.8 |
| mRNA | paclitaxel | gCSI | pan-cancer | AAC | -0.014 | 0.8 |